BioCardia Q2 net loss $2M, cash ~$1.1M after ATM; runway into Oct 2025

BioCardia, Inc.

Net loss of $2.0M for Q2 2025 vs $1.6M in Q2 2024; R&D expenses up to $1.4M.
Cash balance $980k at June 30; raised $769k via ATM at avg $2.59/share; runway into Oct 2025.
R&D expenses increased due to closeout of CardiAMP HF trial and start of CardiAMP HF II enrollment.
Phase 3 CardiAMP HF data submitted to Japan PMDA; FDA meetings on approvability expected Q4 2025.
Helix transendocardial delivery system DeNovo 510(k) submission planned Q3 2025.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.